Pharnext Logo

Pharnext

Develops therapies for neurodegenerative diseases by combining existing drugs.

ALPHA | Euronext Growth

Overview

Corporate Details

ISIN(s):
FR0011191287 (+4 more)
LEI:
969500KJGF9ZUYXSMJ27
Country:
France
Address:
9 RUE DES FILLES SAINT-THOMAS, 75002 PARIS

Description

Pharnext is an advanced clinical-stage biopharmaceutical company that develops novel therapeutics for neurodegenerative diseases lacking curative or satisfactory treatments. The company's approach is based on its proprietary Pleotherapy™ platform, which uses network pharmacology to identify and develop synergistic combinations of already-approved drugs at new, lower doses. This strategy aims to create more effective and safer treatments. Pharnext's lead product candidate, PXT3003, is an oral fixed-dose combination therapy in development for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A), a rare, debilitating inherited peripheral neuropathy.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-08-27 13:00
Ouverture d'une procédure de liquidation judiciaire
French 194.1 KB
2024-08-01 18:00
Ajustement de la valeur nominale
French 189.9 KB
2024-07-18 18:00
Point concernant l'accord de financement en obligations convertibles accordé pa…
French 194.2 KB
2024-07-15 18:00
Demande d'ouverture d'une procédure de liquidation judiciaire
French 193.2 KB
2024-07-10 08:00
Pharnext fait un point sur sa situation financière
French 191.6 KB
2024-07-04 20:00
Pharnext annonce la résiliation du contrat de financement accordé par Néovacs
French 232.3 KB
2024-07-03 08:00
Pharnext fait un point sur les conséquences de sa situation stratégique et fina…
French 208.2 KB
2024-07-01 18:30
Information relative au nombre total de droits de vote et d'actions composant l…
French 185.7 KB
2024-06-28 08:00
Pharnext fait un point d'étape sur les dernières avancées majeures d'un point d…
French 209.3 KB
2024-06-18 18:30
Pharnext annonce la prorogation de la procédure de conciliation jusqu'au 15 jui…
French 194.9 KB
2024-06-05 18:30
Information relative au nombre total de droits de vote et d'actions composant l…
French 181.3 KB
2024-05-29 18:00
Ajustement de la valeur nominale
French 190.9 KB
2024-05-07 19:10
Ajustement de la valeur nominale
French 190.6 KB
2024-05-06 18:00
Pharnext convoque ses actionnaires en assemblée générale le 10 juin 2024
French 194.7 KB
2024-05-02 18:30
Information relative au nombre total de droits de vote et d'actions composant l…
French 195.4 KB

Automate Your Workflow. Get a real-time feed of all Pharnext filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Pharnext

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Pharnext via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

CELADON PHARMACEUTICALS PLC Logo
Researches, cultivates, and manufactures cannabinoid-based medicines for chronic pain.
United Kingdom
CEL
Celemics, Inc. Logo
Develops NGS target enrichment solutions for research and clinical applications.
South Korea
331920
Develops radiopharmaceuticals and radioligand therapies for oncology.
South Korea
308430
CELL BIOTECH CO ., LTD Logo
Develops and manufactures probiotic solutions using patented dual-coating technology.
South Korea
049960
Celldex Therapeutics, Inc. Logo
Develops antibody-based immunotherapies for severe inflammatory and allergic diseases.
United States of America
CLDX
Cellectar Biosciences, Inc. Logo
Clinical-stage biopharma developing targeted cancer treatments via a PDC platform.
United States of America
CLRB
Cellectis Logo
Develops allogeneic, or 'off-the-shelf', CAR T-cell immunotherapies for cancer.
France
ALCLS
Cellid Co., Ltd. Logo
Develops immunotherapeutic vaccines for cancer and infectious diseases.
South Korea
299660
Cellromax Science Co., Ltd. Logo
Researches and develops health foods, derma-cosmetics, and OTC pharmaceuticals.
South Korea
471820
CellSeed Inc. Logo
Develops and commercializes cell sheet engineering for regenerative medicine.
Japan
7776

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.